Bristol-Myers Squibb Company Ce Intangible Assets

The latest intangible assets for CELG-RI is $16B as of September 2019. That compares with $16B in the prior-year period — up 0.3% year over year. Investors often review this figure alongside Bristol-Myers Squibb Company Ce's historical trend and sector peers before judging valuation or financial health.

Over the past year, CELG-RI's intangible assets moved from $16B to $16B — a 0.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb Company Ce's operating scale or balance-sheet position.

A intangible assets figure of $16B for CELG-RI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CELG-RI's intangible assets ($16B), review year-over-year change from $16B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.